Safety and efficacy of zuranolone in Japanese adults with major depressive disorder: An open‐label, repeated‐treatment part of a Phase 3 clinical trial
In this open-label part of the Phase 3 study in Japan, zuranolone decreased the HAMD-17 total scores from baseline over 15 days during repeated treatment cycles in patients with major depressive disorder, without any new safety signals.
Authors
- Takamichi Baba (ORCID: https://orcid.org/0000-0002-4968-2642)
- Masaki Kato (ORCID: https://orcid.org/0009-0006-0846-4047)
- Takuhiro Sonoyama (ORCID: https://orcid.org/0009-0005-1734-8446)
- Tomoko Motomiya (ORCID: https://orcid.org/0000-0002-2558-4263)
- Hiroki Fukuju (ORCID: https://orcid.org/0009-0001-8990-8175)
- Kazuyuki Nakagome
- Ryosuke Shimizu
- Takeshi Inoue
- Juan Carlos Gomez
Institutions
- Kansai Medical University (JP)
- Tokyo Medical University (JP)
- Centre for Innovation in Regulatory Science (GB)
- National Center of Neurology and Psychiatry (JP)
- Shionogi (Japan) (JP)
- Hanazono Hospital (JP)
- Futaba (Japan) (JP)
Publication Details
- Journal
- Psychiatry and Clinical Neurosciences Reports
- Published
- 2026-02-19
- DOI
- https://doi.org/10.1002/pcn5.70302
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sage Therapeutics
- Supernus Pharmaceuticals
- Shionogi